Boxer Capital Management LLC Purchases New Shares in AnaptysBio, Inc. (NASDAQ:ANAB)

Boxer Capital Management LLC bought a new stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 1,300,000 shares of the biotechnology company's stock, valued at approximately $17,212,000. AnaptysBio makes up about 1.5% of Boxer Capital Management LLC's holdings, making the stock its 21st largest position. Boxer Capital Management LLC owned about 4.27% of AnaptysBio as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC increased its stake in shares of AnaptysBio by 131.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 2,697 shares of the biotechnology company's stock worth $36,000 after purchasing an additional 1,531 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of AnaptysBio in the fourth quarter valued at approximately $40,000. AlphaQuest LLC boosted its stake in shares of AnaptysBio by 1,891.5% in the fourth quarter. AlphaQuest LLC now owns 4,461 shares of the biotechnology company's stock worth $59,000 after acquiring an additional 4,237 shares during the last quarter. Virtus ETF Advisers LLC increased its position in shares of AnaptysBio by 24.7% during the fourth quarter. Virtus ETF Advisers LLC now owns 4,733 shares of the biotechnology company's stock worth $63,000 after purchasing an additional 936 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its stake in AnaptysBio by 1,585.8% in the 4th quarter. Russell Investments Group Ltd. now owns 5,698 shares of the biotechnology company's stock valued at $75,000 after purchasing an additional 5,360 shares during the last quarter.

AnaptysBio Stock Up 0.2 %

Shares of ANAB traded up $0.05 on Wednesday, reaching $20.17. The stock had a trading volume of 132,276 shares, compared to its average volume of 591,592. AnaptysBio, Inc. has a twelve month low of $12.21 and a twelve month high of $41.31. The firm has a market capitalization of $596.36 million, a PE ratio of -3.31 and a beta of -0.20. The firm has a 50-day moving average of $18.39 and a 200 day moving average of $18.92.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The biotechnology company reported ($1.28) EPS for the quarter, beating analysts' consensus estimates of ($1.30) by $0.02. The firm had revenue of $27.77 million for the quarter, compared to analysts' expectations of $15.27 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. On average, sell-side analysts anticipate that AnaptysBio, Inc. will post -6.08 earnings per share for the current fiscal year.

AnaptysBio declared that its Board of Directors has approved a share buyback plan on Monday, March 24th that allows the company to repurchase $75.00 million in outstanding shares. This repurchase authorization allows the biotechnology company to reacquire up to 13.1% of its shares through open market purchases. Shares repurchase plans are often an indication that the company's management believes its stock is undervalued.

Analyst Upgrades and Downgrades

ANAB has been the topic of a number of recent research reports. Johnson Rice restated a "buy" rating on shares of AnaptysBio in a research report on Wednesday, March 26th. Wedbush reaffirmed an "outperform" rating and set a $40.00 price target on shares of AnaptysBio in a research report on Thursday, May 1st. JPMorgan Chase & Co. raised their target price on AnaptysBio from $36.00 to $42.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. Wells Fargo & Company upped their price target on AnaptysBio from $40.00 to $51.00 and gave the company an "overweight" rating in a research note on Thursday, February 13th. Finally, Wolfe Research initiated coverage on shares of AnaptysBio in a report on Tuesday, February 4th. They issued an "outperform" rating and a $25.00 price objective on the stock. Four research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $35.88.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.